{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05838625",
            "orgStudyIdInfo": {
                "id": "CT-155-R-001"
            },
            "organization": {
                "fullName": "Click Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia",
            "officialTitle": "A Randomized, Multicenter, 16-week Study to Evaluate the Efficacy and Safety of Two Prescription Digital Therapeutics as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants With Experiential Negative Symptoms of Schizophrenia",
            "acronym": "CONVOKE",
            "therapeuticArea": [
                "Mental Health"
            ],
            "study": "study-of-two-digital-therapeutics-for-the-treatment-of-experiential-negative-symptoms-of-schizophrenia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-18",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07-18",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-20",
            "studyFirstSubmitQcDate": "2023-04-20",
            "studyFirstPostDateStruct": {
                "date": "2023-05-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Click Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Boehringer Ingelheim",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUnapprovedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.",
            "detailedDescription": "The purpose of the proposed study is to evaluate the efficacy and safety of two prescription digital therapeutics as an adjunct treatment to SOC in participants 18 years of age or older diagnosed with experiential negative symptoms of schizophrenia."
        },
        "conditionsModule": {
            "conditions": [
                "Schizophrenia"
            ],
            "keywords": [
                "Prescription digital therapeutic (PDT)",
                "Software as a Medical Device (SaMD)",
                "Smartphone app",
                "Schizophrenia",
                "Negative Symptoms"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 432,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Digital Therapeutic A",
                    "type": "EXPERIMENTAL",
                    "description": "Evaluate the efficacy and safety of digital therapeutic A as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.",
                    "interventionNames": [
                        "Device: Digital Therapeutic"
                    ]
                },
                {
                    "label": "Digital Therapeutic B",
                    "type": "EXPERIMENTAL",
                    "description": "Evaluate the efficacy and safety of digital therapeutic B as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.",
                    "interventionNames": [
                        "Device: Digital Therapeutic"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Digital Therapeutic",
                    "description": "A prescription digital therapeutic in the form of a smartphone app.",
                    "armGroupLabels": [
                        "Digital Therapeutic A",
                        "Digital Therapeutic B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Experiential negative symptoms",
                    "description": "Change from baseline to Week 16 in experiential negative symptoms, as assessed by Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP)",
                    "timeFrame": "Baseline to Week 16"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Motivation and pleasure symptoms",
                    "description": "Change from baseline in motivation and pleasure symptoms at Week 8, as assessed by CAINS-MAP",
                    "timeFrame": "Baseline to Week 8"
                },
                {
                    "measure": "Expressive negative symptoms",
                    "description": "Change from baseline in expressive negative symptoms at Weeks 8 and 16, as assessed by the Clinical Assessment Interview for Negative Symptoms, Expressivity Scale (CAINS-EXP)",
                    "timeFrame": "Baseline to Weeks 8 and 16"
                },
                {
                    "measure": "Positive symptoms",
                    "description": "Change from baseline in positive symptoms at Weeks 8 and 16, as assessed by the Positive and Negative Syndrome Scale (PANSS)",
                    "timeFrame": "Baseline to Weeks 8 and 16"
                },
                {
                    "measure": "Social functioning",
                    "description": "Change from baseline in social functioning at Weeks 8 and 16, as assessed by the Personal and Social Performance Scale (PSP)",
                    "timeFrame": "Baseline to Weeks 8 and 16"
                },
                {
                    "measure": "Self-reported defeatist beliefs",
                    "description": "Change from baseline in self-reported defeatist beliefs at Weeks 8 and 16, as assessed by the Defeatist Beliefs Subscale of the Dysfunctional Attitudes Scale (DAS)",
                    "timeFrame": "Baseline to Weeks 8 and 16"
                },
                {
                    "measure": "Patient global impression of improvement",
                    "description": "Patient Global Impression of Improvement Scale (PGI-I) at Weeks 8 and 16",
                    "timeFrame": "Weeks 8 and 16"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nA participant will be eligible for entry into the study if all of the following criteria are met:\n\n1. Has a primary diagnosis of schizophrenia.\n2. Is on a stable dose of antipsychotic medication(s).\n3. Has obtained an average score of \u22652 (moderate to severe) in at least two of the three CAINS-MAP domains (Social, Work, or Recreational).\n\nExclusion Criteria:\n\nA participant will not be eligible for study entry if any of the following criteria are met:\n\n1. Is currently treated with more than two antipsychotic medications (including more than two dosage forms).\n2. Meets DSM-5, for diagnoses not under investigation.\n3. Has participated in a CT-155 clinical study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Research Coordinator",
                    "role": "CONTACT",
                    "phone": "877-352-5425",
                    "email": "researchcoordinator@clicktherapeutics.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Shaheen Lakhan, MD, PhD, FAAN",
                    "affiliation": "Click Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Click Therapeutics",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10013",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "phone": "877-352-5425",
                            "email": "convokestudy@clicktherapeutics.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012559",
                    "term": "Schizophrenia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019967",
                    "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15376",
                    "name": "Schizophrenia",
                    "asFound": "Schizophrenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21838",
                    "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M16904",
                    "name": "Antipsychotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M6263",
                    "name": "Coal Tar",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                }
            ]
        }
    },
    "hasResults": false
}